ArticleMediators of inflammation2026
IL-6 Exacerbates Experimental Autoimmune Prostatitis by Disrupting STAT5a-Mediated Treg Cell Function and Th17/Treg Balance.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IL-6 Exacerbates Experimental Autoimmune Prostatitis by Disrupting STAT5a-Mediated Treg Cell Function and Th17/Treg Balance.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveChronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common urological condition in men. Although disruption of the Th17 (T helper 17)/Treg (regulatory T) balance has been implicated in its pathogenesis, the upstream drivers of this immune imbalance remain incompletely understood. This study investigated whether interleukin-6 (IL-6) is associated with altered Th17/Treg homeostasis and impaired Treg function in experimental autoimmune prostatitis (EAP).
methodsAn EAP model was generated in NOD mice through immunization with prostate antigen. Th17/Treg cell profiles were determined by flow cytometry, cytokine concentrations by enzyme-linked immunosorbent assay (ELISA), and signal transducer and activator of transcription 5a (STAT5a) expression by western blotting and immunohistochemistry (IHC). In vivo IL-6 inhibition was used to assess its effects on Th17/Treg balance and Treg suppressive function, whereas in vitro experiments examined the effects of IL-6 on Treg function and naïve CD4
resultsRelative to control mice, EAP mice showed higher serum IL-6 concentrations (5.28 ± 0.54 vs. 3.36 ± 0.46 pg/mL, p < 0.01), together with disturbed Th17/Treg homeostasis, as reflected by expansion of Th17 cells (1.72% ± 0.18% vs. 0.98% ± 0.08%, p < 0.001) and reduction of Treg cells (3.99% ± 0.97% vs. 5.46 % ± 0.53%, p < 0.05). Suppressive activity of Treg cells was also diminished (6.56% ± 0.80% vs. 12.41% ± 3.49%, p < 0.05). In vitro, IL-6 shifted naïve CD4
conclusionIL-6 is linked to Th17/Treg imbalance and Treg dysfunction in EAP, possibly through inhibition of STAT5a signaling, and IL-6-related pathways may offer therapeutic value for CP/CPPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.